Evidence map›Paper›PMID 35000580›Full record

ArticleBMC infectious diseases2022

Prevalence of SARS-Cov-2 antibodies and living conditions: the French national random population-based EPICOV cohort.

Josiane Warszawski, Anne-Lise Beaumont, Rémonie Seng, Xavier de Lamballerie, Delphine Rahib, Nathalie Lydié, Rémy Slama, Sylvain Durrleman, Philippe Raynaud, Patrick Sillard and 4 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05336604 (Epidémiologie et Conditions de Vide liées au Covid-19 STUDY OF THE COVID-19), which is not on this map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
5.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05336604 completednot on this map

Epidémiologie et Conditions de Vide liées au Covid-19 STUDY OF THE COVID-19 (SARS-CoV-2) EPIDEMIC AND SOCIO-ECONOMIC LIVING

TypeobservationalSponsorInstitut National de la Santé Et de la Recherche Médicale, FranceRan2020 to 2023Enrolled134,391ConditionsGeneral Population
3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.

  1. Dynamics of SARS-CoV-2 seroassay sensitivity: a systematic review and modelling study.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023
    Pooled it
  2. Article
  3. Article
  4. Relevance and challenges of exposome studies for environmental health research.Environmental health : a global access science source · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Josiane WarszawskiINSERM CESP U1018, Université Paris-Saclay, AP-HP Epidemiology and Public Health Service, Service, Hôpitaux Universitaires Paris-Saclay, 82 rue du Général Leclerc, 94276, Le Kremlin-Bicêtre, France. Josiane.warszawski@inserm.fr.
Anne-Lise BeaumontINSERM CESP U1018, Université Paris-Saclay, AP-HP Epidemiology and Public Health Service, Service, Hôpitaux Universitaires Paris-Saclay, 82 rue du Général Leclerc, 94276, Le Kremlin-Bicêtre, France.
Rémonie SengAP-HP Epidemiology and Public Health Service, Hôpitaux Universitaires Paris-Saclay, Le Kremlin-Bicêtre, France.
Xavier de LamballerieUnité des Virus Emergents, UVE, Aix Marseille Univ, INSERM 1207, IRD 190, Marseille, France.
Delphine RahibSanté Publique France, Saint-Maurice, France.
Nathalie LydiéSanté Publique France, Saint-Maurice, France.
Rémy SlamaInserm, CNRS, Team of Environmental Epidemiology applied to Reproduction and Respiratory Health, Institute for Advanced Biosciences, University Grenoble Alpes, Grenoble, France.
Sylvain DurrlemanInstitut thématique de Santé Publique, INSERM, Paris, France.
Philippe RaynaudDREES - Direction de la Recherche, des Etudes, de l'évaluation et des statistiques, Paris, France.
Patrick SillardInstitut National de la statistique et des études économiques, Montrouge, France.
François BeckSanté Publique France, Saint-Maurice, France.
Laurence MeyerINSERM CESP U1018, Université Paris-Saclay, AP-HP Epidemiology and Public Health Service, Service, Hôpitaux Universitaires Paris-Saclay, 82 rue du Général Leclerc, 94276, Le Kremlin-Bicêtre, France.
Nathalie BajosIRIS, INSERM, EHESS, CNRS, Aubervilliers, France.
EPICOV study group
Inserm · FRSanté Publique France · FRCentre National de la Recherche Scientifique · FRInstitut National de la Statistique et des Etudes Economiques · FRAssistance Publique – Hôpitaux de Paris · FR

Funding

Dr. Bajos has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme 856478
6 · The paper itself

Abstract

backgroundWe aimed to estimate the seroprevalence of SARS-CoV-2 infection in France and to identify the populations most exposed during the first epidemic wave.

methodsRandom selection of individuals aged 15 years or over, from the national tax register (96% coverage). Socio-economic data, migration history, and living conditions were collected via self-computer-assisted-web or computer-assisted-telephone interviews. Home self-sampling was performed for a random subsample, to detect IgG antibodies against spike protein (Euroimmun), and neutralizing antibodies with in-house assays, in dried blood spots (DBS).

resultsThe questionnaire was completed by 134,391 participants from May 2nd to June 2st, 2020, including 17,441 eligible for DBS 12,114 of whom were tested. ELISA-S seroprevalence was 4.5% [95% CI 3.9-5.0] overall, reaching up to 10% in the two most affected areas. High-density residences, larger household size, having reported a suspected COVID-19 case in the household, working in healthcare, being of intermediate age and non-daily tobacco smoking were independently associated with seropositivity, whereas living with children or adolescents did not remain associated after adjustment for household size. Adjustment for both residential density and household size accounted for much of the higher seroprevalence in immigrants born outside Europe, twice that in French natives in univariate analysis.

conclusionThe EPICOV cohort is one of the largest national representative population-based seroprevalence surveys for COVID-19. It shows the major role of contextual living conditions in the initial spread of COVID-19 in France, during which the availability of masks and virological tests was limited.

Indexed as

COVID-19SARS-CoV-2AdolescentAntibodies, ViralChildHumansPrevalenceSeroepidemiologic StudiesAntibodies, ViralCOVID-19Population-based surveyRandom sampleRisk factorsSARS-COV-2Seroprevalence

Identifiers

PMID35000580
PMCPMC8743062
OpenAlexW4205919536

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.